Clinical trial
AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell…
NCT00396968 · Genzyme, a Sanofi Company, Industry · Withdrawn
Key facts
| NCT number | NCT00396968 |
|---|---|
| Title | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS |
| Official title | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | AnorMED Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug, Procedure |
| Interventions | AMD3100, Allogeneic Stem Cell Transplantation |
| Enrollment | 0 |
| First posted | Nov 8, 2006 |
| Last update posted | Feb 11, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: